PLoS ONE · 2014 · 33 citations · 61 references
Life SciencesCell BiologyImmunologyAdaptive ImmunityAutoimmunityImmunotherapyHumoral ImmunityImmune Gene RegulationInterferon ResponsesMultiple SclerosisB Cell-mediated ImmunityB-cell Mediated ImmunityInnate Immune Signaling GenesMultiple Sclerosis Immunopathogenesis
The effects of interferon-beta (IFN-β), one of the key immunotherapies used in multiple sclerosis (MS), on peripheral blood leukocytes and T cells have been extensively studied. B cells are a less abundant leukocyte type, and accordingly less is known about the B cell-specific response to IFN-β. To identify gene expression changes and pathways induced by IFN-β in B cells, we studied the in vitro response of human Epstein Barr-transformed B cells (lymphoblast cell lines-LCLs), and validated our results in primary B cells. LCLs were derived from an MS patient repository. Whole genome expression analysis identified 115 genes that were more than two-fold differentially up-regulated following IFN-β exposure, with over 50 previously unrecognized as IFN-β response genes. Pathways analysis demonstrated that IFN-β affected LCLs in a similar manner to other cell types by activating known IFN-β canonical pathways. Additionally, IFN-β increased the expression of innate immune response genes, while down-regulating many B cell receptor pathway genes and genes involved in adaptive immune responses. Novel response genes identified herein, NEXN, DDX60L, IGFBP4, and HAPLN3, B cell receptor pathway genes, CD79B and SYK, and lymphocyte activation genes, LAG3 and IL27RA, were validated as IFN-β response genes in primary B cells. In this study new IFN-β response genes were identified in B cells, with possible implications to B cell-specific functions. The study's results emphasize the applicability of LCLs for studies of human B cell drug response. The usage of LCLs from patient-based repositories may facilitate future studies of drug response in MS and other immune-mediated disorders with a B cell component.
61
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins, Sam J. Wilson, Maryline Panis et al. · Nature · 2011 · 2.5K citations